PEPG•benzinga•
PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate
Summary
PepGen ends Duchenne drug program after weak Phase 2 results, pivots to DM1 treatment showing early signs of splicing correction and safety.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 29, 2025 by benzinga